Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Consolidated Statements of Financial Position

v3.19.1
Consolidated Statements of Financial Position - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents $ 117,967 $ 165,629
Short term investments (note 5) 7,889 7,833
Accounts receivable and accrued interest receivable 217 109
Prepaid expenses, deposits and other 6,775 1,681
Current assets 132,848 175,252
Clinical trial contract deposits 358 448
Property and equipment (note 6) 41 31
Acquired intellectual property and other intangible assets (note 7) 12,616 14,116
Assets 145,863 189,847
Current liabilities    
Accounts payable and accrued liabilities (note 8) 7,071 7,959
Current portion of deferred revenue (note 9) 118 118
Contingent consideration (note 10) 72 73
Current liabilities 7,261 8,150
Deferred revenue (note 9) 324 442
Contingent consideration (note 10) 3,956 3,719
Derivative warrant liabilities (notes 11 and 23) 21,747 11,793
Liabilities 33,288 24,104
Share capital    
Common shares (note 12) 504,650 499,200
Warrants (note 12) 0 906
Contributed surplus 24,690 18,360
Accumulated other comprehensive loss (805) (883)
Deficit (415,960) (351,840)
Equity 112,575 165,743
Equity and liabilities 145,863 189,847
Commitments and contingencies (note 20)